Partnering

Developing state of the art science with the best partners

Carrick Therapeutics is building an innovative portfolio of first-in-class and best-in-class treatments that target multiple mechanisms driving the most aggressive forms of cancer. We work with partners at every stage of the drug discovery process - from the groups we license our assets from, to the contract research organizations and academics with whom we conduct our studies.

Licensing new opportunities

We are actively seeking new assets that are significantly differentiated and have the potential opportunity for being best-in-class. If you would like to explore partnering opportunities with us and understand how our team of leading experts could help advance your asset, please contact jenny.horsfield@carricktherapeutics.com.

What opportunities are a good fit?

Small molecules, antibodies and antibody drug conjugates (ADCs)
Targeted mode of action
Solid tumor indications
Development stage - lead optimisation to Phase 2 clinical studies
Clear rationale for patient stratification
Opportunity for rapid clinical Proof of Concept
Strong intellectual property position/potential

Explore our pipeline

Why partner with Carrick?

Deeply experienced leadership with a proven record of success

Carrick Therapeutics is founded on a highly-experienced team which has brought together, scientific, clinical and commercial, with a proven track record of identifying and developing commercially-successful innovative medicines.

Our collaborative network includes leading oncology researchers from institutions including Imperial College London, The Royal College of Surgeons Dublin, The Dana-Farber Cancer Institute Boston and The University of Pennsylvania Philadelphia.

Financial backing

Carrick Therapeutics was launched on the back of a $95M funding series A/B round led by a group of strong healthcare investors, with outstanding records of success in accelerating the development of cutting-edge science into new therapies. Subsequently, Carrick has raised a $25M Series C from the original investors and a $35M Series D investment from Pfizer.